Elicio Therapeutics (ELTX) EPS (Weighted Average and Diluted) (2020 - 2026)
Elicio Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.65 for Q1 2026, up 25.29% year-on-year from -$0.52 in Q1 2025, and down 32.65% on a QoQ basis from -$0.49 in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.65 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 25.29% year-over-year to -$0.65; the trailing twelve-month figure through Mar 2026 stood at -$2.4 (up 38.78% YoY), and the FY2025 full-year result was -$2.58, up 39.29% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.65, down from -$0.49 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.21 in Q4 2023 and bottomed at -$24.77 in Q1 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.02 (2024), against an average of -$6.08.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 98.99% in 2023, while the deepest fall reached 5060.42% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$20.75 in 2022, then jumped by 98.99% to -$0.21 in 2023, then slumped by 385.71% to -$1.02 in 2024, then soared by 51.96% to -$0.49 in 2025, then slumped by 32.65% to -$0.65 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.65 (Q1 2026), -$0.49 (Q4 2025), and -$0.6 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -0.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.65 |
| Dec 31, 2025 | -0.49 |
| Sep 30, 2025 | -0.60 |
| Jun 30, 2025 | -0.66 |
| Mar 31, 2025 | -0.87 |
| Dec 31, 2024 | -1.02 |
| Sep 30, 2024 | -1.39 |
| Jun 30, 2024 | -0.64 |
| Mar 31, 2024 | -1.15 |
| Dec 31, 2023 | -0.21 |
| Sep 30, 2023 | -1.27 |
| Jun 30, 2023 | -2.61 |
| Mar 31, 2023 | -24.77 |
| Dec 31, 2022 | -20.75 |
| Sep 30, 2022 | -22.67 |
| Jun 30, 2022 | -23.20 |
| Mar 31, 2022 | -0.48 |
| Dec 31, 2021 | 0.58 |
| Sep 30, 2021 | -0.53 |
| Jun 30, 2021 | -0.58 |
| Mar 31, 2021 | -1.56 |
| Dec 31, 2020 | -1.92 |
| Sep 30, 2020 | -1.19 |
| Jun 30, 2020 | -1.40 |
| Mar 31, 2020 | -0.91 |